FMC85112
Mouse
Mouse
IgG2a, kappa
Monoclonal
PE
Leukocyte antigen CD37, CD37
0.5 mg/ml
Please contact with the lab for this information.
ELISA, FCM
Liquid
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Store at 4°C for 12 months. Protect from light. Do not freeze.
252-3#
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
CD37 in acute myeloid leukemia: a novel surface target for drug delivery., PMID:39348689
CD37 in acute myeloid leukemia: a novel surface target for drug delivery., PMID:39348689
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies., PMID:38846084
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies., PMID:38846084
Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions., PMID:38625120
Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions., PMID:38625120
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
β-Lapachone Exerts Anticancer Effects by Downregulating p53, Lys-Acetylated Proteins, TrkA, p38 MAPK, SOD1, Caspase-2, CD44 and NPM in Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells., PMID:37373014
β-Lapachone Exerts Anticancer Effects by Downregulating p53, Lys-Acetylated Proteins, TrkA, p38 MAPK, SOD1, Caspase-2, CD44 and NPM in Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells., PMID:37373014
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome., PMID:35914223
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome., PMID:35914223
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?, PMID:35486292
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?, PMID:35486292
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma., PMID:35428777
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma., PMID:35428777
Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004
Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia., PMID:33683501
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia., PMID:33683501
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma., PMID:33652767
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma., PMID:33652767
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:33523334
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:33523334
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies., PMID:33333768
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies., PMID:33333768
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma., PMID:33259039
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma., PMID:33259039
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma., PMID:33196921
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma., PMID:33196921
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:32877524
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:32877524
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma., PMID:32578153
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma., PMID:32578153
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32474843
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32474843
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies., PMID:32341336
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies., PMID:32341336
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003., PMID:32187209
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003., PMID:32187209
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32172489
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32172489
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest., PMID:31836849
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest., PMID:31836849
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine., PMID:31481583
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine., PMID:31481583
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003., PMID:31309259
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003., PMID:31309259
Functional study of 14-3-3 protein epsilon (YWHAE) in keratinocytes: microarray integrating bioinformatics approaches., PMID:31244373
Functional study of 14-3-3 protein epsilon (YWHAE) in keratinocytes: microarray integrating bioinformatics approaches., PMID:31244373
New drugs for old targets., PMID:31187537
New drugs for old targets., PMID:31187537
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia., PMID:31089249
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia., PMID:31089249
Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer., PMID:30941556
Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer., PMID:30941556
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering., PMID:30792198
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering., PMID:30792198
Effect of classical conditioning over immature and mature B lymphocytes regulation., PMID:30365190
Effect of classical conditioning over immature and mature B lymphocytes regulation., PMID:30365190
Anti-CD37 targeted immunotherapy of B-Cell malignancies., PMID:30293139
Anti-CD37 targeted immunotherapy of B-Cell malignancies., PMID:30293139
Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma., PMID:29993152
Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma., PMID:29993152
Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice., PMID:29551516
Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice., PMID:29551516
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients., PMID:29470615
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients., PMID:29470615
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study., PMID:29453628
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study., PMID:29453628
Non-IgE mediated mast cell activation., PMID:29431205
Non-IgE mediated mast cell activation., PMID:29431205
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies., PMID:29323537
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies., PMID:29323537
CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy., PMID:28855210
CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy., PMID:28855210
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:28848035
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:28848035
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models., PMID:28753442
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models., PMID:28753442
Novel Insights into Membrane Targeting of B Cell Lymphoma., PMID:28718418
Novel Insights into Membrane Targeting of B Cell Lymphoma., PMID:28718418
A role for the tetraspanin proteins in Salmonella infection of human macrophages., PMID:28602860
A role for the tetraspanin proteins in Salmonella infection of human macrophages., PMID:28602860
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia., PMID:27977057
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia., PMID:27977057
New emerging therapies in the management of chronic lymphocytic leukemia., PMID:27899962
New emerging therapies in the management of chronic lymphocytic leukemia., PMID:27899962
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment., PMID:27834943
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment., PMID:27834943
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate., PMID:27587710
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate., PMID:27587710
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:27493270
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:27493270
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma., PMID:27416486
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma., PMID:27416486
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia., PMID:27040707
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia., PMID:27040707
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
